{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:30:07Z","timestamp":1792459807215,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1038\/leu.2015.60","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T07:33:25Z","timestamp":1426232005000},"page":"1695-1701","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-5688","authenticated-orcid":false,"given":"G","family":"Hess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C W","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Atta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kirschey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ruckes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Medler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"van Oordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Theobald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"key":"BFleu201560_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235\u2013242.","journal-title":"N Engl J Med"},{"key":"BFleu201560_CR2","first-page":"352a","volume":"102","author":"W Hiddemann","year":"2003","unstructured":"Hiddemann W, Dreyling M, Forstpointner R, Kneba M, Woermann B, Lengfelder E et al. Combined immunochemotherpy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003; 102: 352a.","journal-title":"Blood"},{"key":"BFleu201560_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520\u2013531.","journal-title":"N Engl J Med"},{"key":"BFleu201560_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/10428190400029841","volume":"46","author":"DW Thomas","year":"2005","unstructured":"Thomas DW, Owen RG, Johnson SA, Hillmen P, Seymour JF, Wolf MM et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005; 46: 549\u2013552.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201560_CR5","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"R Advani","year":"2013","unstructured":"Advani R, Buggy J, Sharman J, Smith S, Boyd T, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88\u201394.","journal-title":"J Clin Oncol"},{"issue":"11","key":"BFleu201560_CR7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"Ajay K. Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370: 1008\u20131018.","journal-title":"New England Journal of Medicine"},{"key":"BFleu201560_CR8","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867\u20134874.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR9","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622\u20131627.","journal-title":"Ann Oncol"},{"key":"BFleu201560_CR10","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","volume":"12","author":"M Hidalgo","year":"2006","unstructured":"Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006; 12: 5755\u20135763.","journal-title":"Clin Cancer Res"},{"key":"BFleu201560_CR11","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1017\/S1462399408000586","volume":"10","author":"E Drakos","year":"2008","unstructured":"Drakos E, Rassidakis GZ, Medeiros LJ . Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med 2008; 10: e4.","journal-title":"Expert Rev Mol Med"},{"key":"BFleu201560_CR12","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","volume":"169","author":"E Peponi","year":"2006","unstructured":"Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ . Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006; 169: 2171\u20132180.","journal-title":"Am J Pathol"},{"key":"BFleu201560_CR13","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347\u20135356.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.23580","volume":"113","author":"SM Ansell","year":"2008","unstructured":"Ansell SM, Inwards DJ, Rowland KM Jr, Flynn PJ, Morton RF, Moore DF Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508\u2013514.","journal-title":"Cancer"},{"key":"BFleu201560_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","volume":"97","author":"C Renner","year":"2012","unstructured":"Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F et al. A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97: 1085\u20131091.","journal-title":"Haematologica"},{"key":"BFleu201560_CR16","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2008","unstructured":"Hess G, Romaguera J, Verhoef G, Herbrecht R, Crump M, Strahs A et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J Clin Oncol 2008; 27: 3822\u20133829, (May 20 suppl; abstr 8513).","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1586\/ehm.09.57","volume":"2","author":"G Hess","year":"2009","unstructured":"Hess G . Temsirolimus for the treatment of mantle cell lymphoma. Expert Rev Hematol 2009; 2: 631\u2013640.","journal-title":"Expert Rev Hematol"},{"key":"BFleu201560_CR18","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","volume":"28","author":"SM Smith","year":"2010","unstructured":"Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740\u20134746.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.leukres.2009.01.039","volume":"33","author":"SS Farag","year":"2009","unstructured":"Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, Chan K et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009; 33: 1475\u20131480.","journal-title":"Leuk Res"},{"key":"BFleu201560_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-8722-3-30","volume":"3","author":"L Wang","year":"2010","unstructured":"Wang L, Shi WY, Wu ZY, Varna M, Wang AH, Zhou L et al. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol 2010; 3: 30.","journal-title":"J Hematol Oncol"},{"key":"BFleu201560_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-010-0951-z","volume":"90","author":"P Kiewe","year":"2011","unstructured":"Kiewe P, Thiel E . Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma. Ann Hematol 2011; 90: 109\u2013110.","journal-title":"Ann Hematol"},{"key":"BFleu201560_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361\u2013368.","journal-title":"Lancet Oncol"},{"key":"BFleu201560_CR23","first-page":"3661","volume":"120","author":"DJ Inwards","year":"2012","unstructured":"Inwards DJ, Fishkin P, LaPlant BR, Drake MT, Kurtin P, Nikcevich D et al. Phase I trial of Rituximab, Cladribine and Temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ASH Annu Meeting Abstr 2012; 120: 3661.","journal-title":"ASH Annu Meeting Abstr"},{"key":"BFleu201560_CR24","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383\u20133389.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203\u20131210.","journal-title":"Lancet"},{"key":"BFleu201560_CR26","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473\u20134479.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR27","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR28","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830\u2013837.","journal-title":"Nat Genet"},{"key":"BFleu201560_CR29","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","volume":"31","author":"C Visco","year":"2013","unstructured":"Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R et al. Combination of Rituximab, Bendamustine, and Cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442\u20131449.","journal-title":"J Clin Oncol"},{"key":"BFleu201560_CR30","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/10428190701361828","volume":"48","author":"R Weide","year":"2007","unstructured":"Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A et al. High anti-lymphoma activity of bendamustine\/mitoxantrone\/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48: 1299\u20131306.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201560_CR31","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807\u20132812.","journal-title":"Blood"},{"key":"BFleu201560_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00277-012-1422-5","volume":"91","author":"L Rigacci","year":"2012","unstructured":"Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D\u2019Arco A et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin\u2019s lymphoma patients. Ann Hematol 2012; 91: 1013\u20131022.","journal-title":"Ann Hematol"},{"key":"BFleu201560_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/cncr.28405","volume":"120","author":"T Ahmadi","year":"2014","unstructured":"Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2014; 120: 222\u2013228.","journal-title":"Cancer"},{"key":"BFleu201560_CR34","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol 2012; 13: 716\u2013723.","journal-title":"Lancet Oncol"},{"key":"BFleu201560_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507\u2013516.","journal-title":"N Engl J Med"},{"key":"BFleu201560_CR36","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27: 1902\u20131909.","journal-title":"Leukemia"},{"key":"BFleu201560_CR37","doi-asserted-by":"crossref","unstructured":"Wang M, Hagemeister F, Westin J, Fayad L, Samaniego F, Turtorro F et al Ibrutinib and Rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase ii clinical trial. ASH Annu Meeting Abstr 2014 (abstract 627).","DOI":"10.1182\/blood.V124.21.627.627"},{"key":"BFleu201560_CR38","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR et al. A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398\u20133405.","journal-title":"Blood"},{"key":"BFleu201560_CR39","doi-asserted-by":"crossref","unstructured":"Trneny M, Lamy T, Walewski J, Jurczak W, Belada D, Mayer J et al. Phase II randomized, multicenter study of lenalidomide vs best investigator\u2019s choice in relapsed\/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) Study. ASH Annu Meeting Abstr 2014; abstract 626.","DOI":"10.1182\/blood.V124.21.626.626"},{"key":"BFleu201560_CR40","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3324\/haematol.2011.051813","volume":"97","author":"F Zaja","year":"2012","unstructured":"Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F et al. Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416\u2013422.","journal-title":"Haematologica"},{"key":"BFleu201560_CR41","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","volume":"96","author":"W Lamm","year":"2011","unstructured":"Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96: 1008\u20131014.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201560","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:23:15Z","timestamp":1648743795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["BFleu201560"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.60","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,13]]},"assertion":[{"value":"26 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Johannes Atta received honoraria from Pfizer and Roche. Christian Buske received honoraria and research funding from Roche and Janssen and honoraria from Pfizer and Pharmacyclics. Martin Dreyling received research funding and speaker\u2019s honoraria from Pfizer, Mundipharma and Roche. Georg Hess received research funding and honoraria from and is on the advisory committee of Pfizer, research funding from Mundipharma and honoraria from and is on the advisory committee of Roche. Ulrich Keller received honoraria from and is on the advisory committee of Pfizer and speaker and advisory board honoraria from Mundipharma and Roche. Christian Scholz received honoraria from and is on the advisory committee of Pfizer, research funding and honoraria from and is on the advisory committee of Mundipharma and honoraria from and is on the advisory committee of Roche. Mathias Witzens-Harig received research funding and honoraria from and is on the advirsory committee of Pfizer and Roche and honoraria from Mundipharma. The other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}